Mi-Kyoung Kwak

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/600247/publications.pdf

Version: 2024-02-01

117625 161849 5,276 61 34 54 citations g-index h-index papers 61 61 61 7288 docs citations times ranked citing authors all docs

#	Article	IF	Citations
1	High Levels of Hyaluronic Acid Synthase-2 Mediate NRF2-Driven Chemoresistance in Breast Cancer Cells. Biomolecules and Therapeutics, 2022, 30, 368-379.	2.4	7
2	Negative correlation of urinary miR-199a-3p level with ameliorating effects of sarpogrelate and cilostazol in hypertensive diabetic nephropathy. Biochemical Pharmacology, 2021, 184, 114391.	4.4	6
3	The multifaceted role of NRF2 in cancer progression and cancer stem cells maintenance. Archives of Pharmacal Research, 2021, 44, 263-280.	6.3	23
4	Role of CD133/NRF2 Axis in the Development of Colon Cancer Stem Cell-Like Properties. Frontiers in Oncology, 2021, 11, 808300.	2.8	16
5	NRF2 level is negatively correlated with TGF- \hat{l}^21 -induced lung cancer motility and migration via NOX4-ROS signaling. Archives of Pharmacal Research, 2020, 43, 1297-1310.	6.3	20
6	Inhibition of cytochrome P450 2B6 by Astragalus extract mixture HT042. Toxicological Research, 2020, 36, 195-201.	2.1	1
7	Impairment of HIF-1α-mediated metabolic adaption by NRF2-silencing in breast cancer cells. Redox Biology, 2019, 24, 101210.	9.0	73
8	Bardoxolone ameliorates TGF- \hat{l}^21 -associated renal fibrosis through Nrf2/Smad7 elevation. Free Radical Biology and Medicine, 2019, 138, 33-42.	2.9	62
9	High CD44 expression mediates p62-associated NFE2L2/NRF2 activation in breast cancer stem cell-like cells: Implications for cancer stem cell resistance. Redox Biology, 2018, 17, 246-258.	9.0	115
10	Regulatory crosstalk between the oxidative stress-related transcription factor Nfe2l2/Nrf2 and mitochondria. Toxicology and Applied Pharmacology, 2018, 359, 24-33.	2.8	172
11	High NRF2 level mediates cancer stem cell-like properties of aldehyde dehydrogenaseÂ(ALDH)-high ovarian cancer cells: inhibitory role of all-trans retinoic acid in ALDH/NRF2 signaling. Cell Death and Disease, 2018, 9, 896.	6.3	90
12	Overexpression of CD44 Standard Isoform Upregulates HIF- $1\hat{l}\pm$ Signaling in Hypoxic Breast Cancer Cells. Biomolecules and Therapeutics, 2018, 26, 487-493.	2.4	14
13	Inhibitory role of Nfe2l2 (Nrf2) in Tgf-beta1-Smad signaling through Smad7 elevation in mouse mesangial MES-13 cell. Proceedings for Annual Meeting of the Japanese Pharmacological Society, 2018, WCP2018, PO1-3-20.	0.0	0
14	Role of Nrf2 in drug resistance of cancer stem-like cells. Proceedings for Annual Meeting of the Japanese Pharmacological Society, 2018, WCP2018, SY21-3.	0.0	0
15	Hyaluronan synthase HAS2 promotes chemoresistance by upregulating NRF2 expression. Proceedings for Annual Meeting of the Japanese Pharmacological Society, 2018, WCP2018, PO4-6-45.	0.0	0
16	Amelioration of high fat diet-induced nephropathy by cilostazol and rosuvastatin. Archives of Pharmacal Research, 2017, 40, 391-402.	6.3	15
17	Tempo-spatial Activation of Sequential Quadruple Stimuli for High Gene Expression of Polymeric Gene Nanocomplexes. Molecular Pharmaceutics, 2017, 14, 842-855.	4.6	3
18	NFE2L2/NRF2 Activity Is Linked to Mitochondria and AMP-Activated Protein Kinase Signaling in Cancers Through miR-181c/Mitochondria-Encoded Cytochrome c Oxidase Regulation. Antioxidants and Redox Signaling, 2017, 27, 945-961.	5.4	45

#	Article	IF	Citations
19	NFE2L2/NRF2 silencing-inducible miR-206 targets c-MET/EGFR and suppresses BCRP/ABCG2 in cancer cells. Oncotarget, 2017, 8, 107188-107205.	1.8	26
20	Redox Modulating NRF2: A Potential Mediator of Cancer Stem Cell Resistance. Oxidative Medicine and Cellular Longevity, 2016, 2016, 1-14.	4.0	103
21	Pravastatin and Sarpogrelate Synergistically Ameliorate Atherosclerosis in LDLr-Knockout Mice. PLoS ONE, 2016, 11, e0150791.	2.5	5
22	Shadows of NRF2 in cancer: Resistance to chemotherapy. Current Opinion in Toxicology, 2016, 1, 20-28.	5.0	30
23	Beneficial Effects of Sarpogrelate and Rosuvastatin in High Fat Diet/Streptozotocin-Induced Nephropathy in Mice. PLoS ONE, 2016, 11, e0153965.	2.5	28
24	Involvement of NRF2 Signaling in Doxorubicin Resistance of Cancer Stem Cell-Enriched Colonospheres. Biomolecules and Therapeutics, 2016, 24, 482-488.	2.4	52
25	The c-MET/PI3K Signaling Is Associated with Cancer Resistance to Doxorubicin and Photodynamic Therapy by Elevating BCRP/ABCG2 Expression. Molecular Pharmacology, 2015, 87, 465-476.	2.3	50
26	Regulation of the expression of renal drug transporters in KEAP1-knockdown human tubular cells. Toxicology in Vitro, 2015, 29, 884-892.	2.4	29
27	Involvement of Nrf2-GSH signaling in TGF \hat{I}^21 -stimulated epithelial-to-mesenchymal transition changes in rat renal tubular cells. Archives of Pharmacal Research, 2015, 38, 272-281.	6.3	39
28	NRF2 Signaling Negatively Regulates Phorbol-12-Myristate-13-Acetate (PMA)-Induced Differentiation of Human Monocytic U937 Cells into Pro-Inflammatory Macrophages. PLoS ONE, 2015, 10, e0134235.	2.5	37
29	Activation of NRF2 by p62 and proteasome reduction in sphere-forming breast carcinoma cells. Oncotarget, 2015, 6, 8167-8184.	1.8	68
30	Inhibitory Role of the KEAP1-NRF2 Pathway in $TGF\hat{l}^2$ 1-Stimulated Renal Epithelial Transition to Fibroblastic Cells: A Modulatory Effect on SMAD Signaling. PLoS ONE, 2014, 9, e93265.	2.5	65
31	Effect of Redox Modulating NRF2 Activators on Chronic Kidney Disease. Molecules, 2014, 19, 12727-12759.	3.8	135
32	The Sensitivity of Cancer Cells to Pheophorbide a-Based Photodynamic Therapy Is Enhanced by NRF2 Silencing. PLoS ONE, 2014, 9, e107158.	2.5	54
33	Caffeic acid phenethyl ester activation of Nrf2 pathway is enhanced under oxidative state: Structural analysis and potential as a pathologically targeted therapeutic agent in treatment of colonic inflammation. Free Radical Biology and Medicine, 2013, 65, 552-562.	2.9	47
34	Where are we now in diabetic research?. Archives of Pharmacal Research, 2013, 36, 142-144.	6.3	2
35	Identification of aldo-keto reductases as NRF2-target marker genes in human cells. Toxicology Letters, 2013, 218, 39-49.	0.8	91
36	Silver nanoparticles-mediated G2/M cycle arrest of renal epithelial cells is associated with NRF2-GSH signaling. Toxicology Letters, 2012, 211, 334-341.	0.8	52

#	Article	IF	CITATIONS
37	Involvement of the Nrf2-proteasome pathway in the endoplasmic reticulum stress response in pancreatic \hat{l}^2 -cells. Toxicology and Applied Pharmacology, 2012, 264, 431-438.	2.8	54
38	NRF2 inhibition represses ErbB2 signaling in ovarian carcinoma cells: Implications for tumor growth retardation and docetaxel sensitivity. Free Radical Biology and Medicine, 2012, 52, 1773-1785.	2.9	39
39	Role of the Nrf2-heme oxygenase-1 pathway in silver nanoparticle-mediated cytotoxicity. Toxicology and Applied Pharmacology, 2012, 258, 89-98.	2.8	69
40	Suppression of Nrf2 signaling by angiotensin II in murine renal epithelial cells. Archives of Pharmacal Research, 2011, 34, 829-836.	6.3	26
41	NRF2 Blockade Suppresses Colon Tumor Angiogenesis by Inhibiting Hypoxia-Induced Activation of HIF- $1\hat{l}\pm$. Cancer Research, 2011, 71, 2260-2275.	0.9	249
42	Effect of stable inhibition of NRF2 on doxorubicin sensitivity in human ovarian carcinoma OV90 cells. Archives of Pharmacal Research, 2010, 33, 717-726.	6.3	21
43	Targeting NRF2 signaling for cancer chemoprevention. Toxicology and Applied Pharmacology, 2010, 244, 66-76.	2.8	263
44	The NRF2–heme oxygenase-1 system modulates cyclosporin A-induced epithelial–mesenchymal transition and renal fibrosis. Free Radical Biology and Medicine, 2010, 48, 1051-1063.	2.9	98
45	Regulation of Notch1 Signaling by Nrf2: Implications for Tissue Regeneration. Science Signaling, 2010, 3, ra52.	3.6	189
46	The Nrf2 System as a Potential Target for the Development of Indirect Antioxidants. Molecules, 2010, 15, 7266-7291.	3.8	380
47	Involvement of NSAIDâ€activated geneâ€1 in a novel synthetic hexahydrocannabinol analogueâ€induced growth inhibition and apoptosis of colon cancer cells. FASEB Journal, 2010, 24, 965.8.	0.5	0
48	Role of NRF2 in cyclosporine Aâ€induced renal fibrosis. FASEB Journal, 2010, 24, 968.4.	0.5	0
49	Acquisition of doxorubicin resistance in ovarian carcinoma cells accompanies activation of the NRF2 pathway. Free Radical Biology and Medicine, 2009, 47, 1619-1631.	2.9	109
50	Role of the Nrf2-antioxidant system in cytotoxicity mediated by anticancer cisplatin: Implication to cancer cell resistance. Cancer Letters, 2008, 260, 96-108.	7.2	145
51	Inhibition of the Nrf2â€Antioxidant Pathway Sensitizes Cells to Alkylating Anticancer Drugs. FASEB Journal, 2008, 22, 1136.17.	0.5	0
52	Tissue specific increase of the catalytic subunits of the 26S proteasome by indirect antioxidant dithiolethione in mice: Enhanced activity for degradation of abnormal protein. Life Sciences, 2007, 80, 2411-2420.	4.3	30
53	Role of increased expression of the proteasome in the protective effects of sulforaphane against hydrogen peroxide-mediated cytotoxicity in murine neuroblastoma cells. Free Radical Biology and Medicine, 2007, 43, 809-817.	2.9	125
54	Induction of 26S proteasome subunit PSMB5 by the bifunctional inducers through the Nrf2â€ARE pathway. FASEB Journal, 2007, 21, A1182.	0.5	0

#	Article	IF	CITATIONS
55	Role of induction of the 26S proteasome in protective effects of sulforaphane against hydrogen peroxideâ€mediated cytotoxicity in murine neuroblastoma cells. FASEB Journal, 2007, 21, A1175.	0.5	1
56	Induction of 26S proteasome subunit PSMB5 by the bifunctional inducer 3-methylcholanthrene through the Nrf2-ARE, but not the AhR/Arnt-XRE, pathway. Biochemical and Biophysical Research Communications, 2006, 345, 1350-1357.	2.1	52
57	Chemoprevention through the Keap1–Nrf2 signaling pathway by phase 2 enzyme inducers. Mutation Research - Fundamental and Molecular Mechanisms of Mutagenesis, 2004, 555, 133-148.	1.0	258
58	Antioxidants Enhance Mammalian Proteasome Expression through the Keap1-Nrf2 Signaling Pathway. Molecular and Cellular Biology, 2003, 23, 8786-8794.	2.3	446
59	Modulation of Gene Expression by Cancer Chemopreventive Dithiolethiones through the Keap1-Nrf2 Pathway. Journal of Biological Chemistry, 2003, 278, 8135-8145.	3.4	611
60	Role of Transcription Factor Nrf2 in the Induction of Hepatic Phase 2 and Antioxidative Enzymes in vivo by the Cancer Chemoprotective Agent, 3H-1, 2-Dithiole-3-thione. Molecular Medicine, 2001, 7, 135-145.	4.4	317
61	Role of phase 2 enzyme induction in chemoprotection by dithiolethiones. Mutation Research - Fundamental and Molecular Mechanisms of Mutagenesis, 2001, 480-481, 305-315.	1.0	219